These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 15880024)

  • 1. Clinical experience with everolimus (Certican): a summary.
    Ponticelli C
    Transplantation; 2005 May; 79(9 Suppl):S93-4. PubMed ID: 15880024
    [No Abstract]   [Full Text] [Related]  

  • 2. Reduction in calcineurin inhibitor exposure and maintenance of effective immunosuppression: clinical experience with everolimus (Certican).
    Monaco AP; Morris PJ
    Transplantation; 2005 May; 79(9 Suppl):S67-8. PubMed ID: 15880017
    [No Abstract]   [Full Text] [Related]  

  • 3. Concentration-controlled everolimus (Certican): combination with reduced dose calcineurin inhibitors.
    Pascual J
    Transplantation; 2005 May; 79(9 Suppl):S76-9. PubMed ID: 15880020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recommendations for the use of everolimus (Certican) in heart transplantation: results from the second German-Austrian Certican Consensus Conference.
    Rothenburger M; Zuckermann A; Bara C; Hummel M; Strüber M; Hirt S; Lehmkuhl H;
    J Heart Lung Transplant; 2007 Apr; 26(4):305-11. PubMed ID: 17403469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Everolimus: a review of its use in renal and cardiac transplantation.
    Dunn C; Croom KF
    Drugs; 2006; 66(4):547-70. PubMed ID: 16597167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between everolimus blood concentration assessed using the Innofluor Certican Fluorescence Polarization Immunoassay and the Architect i System sirolimus chemiluminescent microparticle immunoassay.
    Coentrão L; Carvalho C; Sampaio S; Oliveira JG; Pestana MI
    Transplant Proc; 2010 Jun; 42(5):1867-9. PubMed ID: 20620539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical experience with everolimus (Certican): optimizing dose and tolerability.
    Pascual J; Marcén R; Ortuño J
    Transplantation; 2005 May; 79(9 Suppl):S80-4. PubMed ID: 15880021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Everolimus: a guide to its use in liver transplantation.
    Keating GM; Lyseng-Williamson KA
    BioDrugs; 2013 Aug; 27(4):407-11. PubMed ID: 23696253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sirolimus therapy without calcineurin inhibitors: Necker Hospital 8-year experience.
    Morelon E; Kreis H
    Transplant Proc; 2003 May; 35(3 Suppl):52S-57S. PubMed ID: 12742467
    [No Abstract]   [Full Text] [Related]  

  • 10. Randomized trial of everolimus-facilitated calcineurin inhibitor minimization over 24 months in renal transplantation.
    Cibrik D; Silva HT; Vathsala A; Lackova E; Cornu-Artis C; Walker RG; Wang Z; Zibari GB; Shihab F; Kim YS
    Transplantation; 2013 Apr; 95(7):933-42. PubMed ID: 23422495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of Certican (everolimus, rad) in the many pathways of chronic rejection.
    Nashan B
    Transplant Proc; 2001; 33(7-8):3215-20. PubMed ID: 11750380
    [No Abstract]   [Full Text] [Related]  

  • 12. Certican (Everolimus) in heart transplantation: from clinical trial to clinical experience. Proceedings of a meeting, Vienna, Austria, September 9, 2004.
    J Heart Lung Transplant; 2005 Apr; 24(4 Suppl):S183-211. PubMed ID: 15774319
    [No Abstract]   [Full Text] [Related]  

  • 13. Calcineurin-inhibitor induced pain syndrome after organ transplantation.
    Collini A; De Bartolomeis C; Barni R; Ruggieri G; Bernini M; Carmellini M
    Kidney Int; 2006 Oct; 70(7):1367-70. PubMed ID: 16955101
    [No Abstract]   [Full Text] [Related]  

  • 14. Everolimus (Certican) in combination with neoral in pediatric renal transplant recipients: interim analysis after 3 months.
    Vester U; Kranz B; Wehr S; Boger R; Hoyer PF;
    Transplant Proc; 2002 Sep; 34(6):2209-10. PubMed ID: 12270366
    [No Abstract]   [Full Text] [Related]  

  • 15. Conversion from a calcineurin inhibitor-based immunosuppressive regimen to everolimus in renal transplant recipients: effect on renal function and proteinuria.
    Morales J; Fierro A; Benavente D; Zehnder C; Ferrario M; Contreras L; Herzog C; Buckel E
    Transplant Proc; 2007 Apr; 39(3):591-3. PubMed ID: 17445551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SDZ RAD. Rapamycin SDZ.
    Drugs R D; 1999 Jan; 1(1):97-9. PubMed ID: 10566000
    [No Abstract]   [Full Text] [Related]  

  • 17. [Association of everolimus with tacrolimus during the first year after heart transplantation: initial experience].
    Cardona M; Castel MÁ; Farrero M; Pérez-Villa F
    Med Clin (Barc); 2013 Jul; 141(2):87-8. PubMed ID: 23384432
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparative analysis of adverse events requiring suspension of mTOR inhibitors: everolimus versus sirolimus.
    Sánchez-Fructuoso AI; Ruiz JC; Pérez-Flores I; Gómez Alamillo C; Calvo Romero N; Arias M
    Transplant Proc; 2010 Oct; 42(8):3050-2. PubMed ID: 20970607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [3/3 Inhibitors of mTOR (sirolimus and everolimus)].
    Chaumard N; Limat S; Woronoff-Lemsi MC
    Soins; 2007 Sep; (718):63-4. PubMed ID: 17970580
    [No Abstract]   [Full Text] [Related]  

  • 20. Sirolimus-induced aphthous ulcers which disappeared with conversion to everolimus.
    Ram R; Swarnalatha G; Neela P; Dakshinamurty KV
    Saudi J Kidney Dis Transpl; 2008 Sep; 19(5):819-20. PubMed ID: 18711306
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.